Danish Cancer Institute’s Post

Silexion Therapeutics Corp unveils cutting-edge technology in the fight against KRAS-driven cancers with their proprietary LODER™ platform and SIL-204 siRNA formulation. These innovations target oncogene silencing directly, offering a unique approach compared to traditional KRAS inhibitors. By focusing on localized delivery, Silexion ensures high treatment concentrations within tumors while minimizing systemic side effects. With SIL-204 set to enter Phase 2/3 clinical trials in 2025-2026, Silexion addresses a crucial need by targeting a broader range of KRAS mutations, overcoming limitations seen in current treatments for pancreatic cancer. Their technologies aim to combat the challenges of late detection, aggressive growth, genetic complexity, and chemotherapy resistance associated with this disease. As the prevalence of KRAS-driven cancers rises, Silexion's advancements hold promise for improved treatment outcomes. Positioned in the dynamic landscape of precision oncology, Silexion Therapeutics, a recently de-SPACed company, presents an enticing opportunity for investors seeking involvement in the evolving field of targeted cancer therapies. Learn more about Silexion's groundbreaking RNAi technology here: https://lnkd.in/dZ-rP6Ms Mirit Horenshtein Hadar Nira Nuriely

🧠 Top ten Late-breaking data to look for at ASCO 2024 🧠 #AmericanSocietyofClinicalOncology (ASCO) Annual meeting started on 31st of May to discuss the latest research in cancer therapies. Some of the topics covered: 💡 Moderna and MSD's mRNA-4157 vaccine looks like it could be a "game changer" as the first personalised mRNA cancer immunotherapy for resected melanoma. 💡 Amgen's and Bristol Myers Squibb' KRAS G12C agent showcasing phase III results from their inhibitor candidates. 💡 AstraZeneca discuss two blockbuster drugs-Imfinzi (duralumab) and Tagrisso (Osimertinib)- in SCLC and NSCLC respectfully. 💡 GSK, Pfizer and Novartis all showing positive developments in blood cancers. https://lnkd.in/eZnuvtDk

BiVictriX Therapeutics plc (AIM:BVX, OTC:BVTXF) has reported positive initial results from preclinical testing of its lead solid tumour treatment, BVX002, targeting ovarian cancer. BVX002 is a bispecific antibody-drug conjugate (Bi-Cygni ADC), a targeted cancer treatment that combines two antibodies to specifically attack cancer cells while carrying a powerful drug to kill them. This approach helps focus treatment on cancer cells, reducing damage to healthy cells and lowering side effects. In a mouse model, the drug showed tumour growth reductions between 78.3% and over 100%. Shrinkage of up to 63.1% was observed at mid and high doses. The drug was administered weekly over four doses and was well tolerated even at the highest levels, with no major side effects. More at #Proactive #ProactiveInvestors http://ow.ly/frjA105I699

Unlocking Hope, Delivering Precision – The Heart of Speratum Biopharma, Inc. The name Speratum stems from the Latin word meaning “to hope.” At Speratum Biopharma, hope is not just a sentiment—it’s the foundation of our mission, our science, and our drive to redefine what’s possible in precision oncology. Our journey is rooted in advancing life-changing therapies through rigorous innovation and groundbreaking science. With a focus on microRNA-198 (miRNA-198) and our proprietary Nano-In™ and NoPass™ delivery platforms, we are targeting solid tumors with unparalleled precision. These platforms are designed to deliver therapeutic molecules directly to cancer cells, ensuring safety, efficacy, and targeted intervention. What Drives Us: Our preclinical data has demonstrated: • Exceptional specificity in targeting cancer cells. • Reduced off-target effects compared to traditional therapies. • Enhanced efficacy through advanced delivery mechanisms. Over the past year, our efforts have centered on creating robust datasets that validate our approach. This includes testing in various solid tumor models and refining our platforms to ensure scalability and readiness for clinical application. The Year Ahead: In the next 12 months, we aim to: • Initiate a Phase 1b study to further validate the safety and efficacy of our miRNA-198 therapy. • Expand our pipeline to include additional indications leveraging our delivery technologies. • Forge strategic partnerships that align with our vision to accelerate innovation. • Build a community of collaborators, investors, and scientists united by the promise of defeating the undefeatable. We invite you to join our journey as we push the boundaries of science to bring hope to those who need it most. Visit us at www.speratum.com to learn more about our mission, explore our work, and discover how you can be a part of advancing medicine. Together, we are redefining precision, delivering innovation, and inspiring hope.

**Silexion Therapeutics: A Precision Oncology Powerhouse to Watch** Following the remarkable success of Summit Therapeutics, Silexion Therapeutics (NASDAQ: SLXN) is emerging as a key player in precision oncology. With cutting-edge RNA interference technology, Silexion tackles some of cancer's toughest challenges: KRAS-driven cancers. Pancreatic cancer, notoriously difficult to treat, has shown promising responses to Silexion's therapies. Despite promising clinical results and a compelling approach, Silexion remains undervalued. As it reports positive outcomes in upcoming Phase 2/3 trials, it has the potential to soar, as Summit has done in NSCLC. Silexion's broader approach could transform treatment for multiple aggressive cancers. Watch this company as it advances through clinical development, poised to make a significant impact on precision oncology. https://lnkd.in/dB2yDxeZ

Cell viability assays are fundamental tools for determining cell health and assessing compound cytotoxicity. Choosing the right assay is particularly crucial for high-throughput screening. Discover the reasons why the National Cancer Institute has adopted the CellTiter-Glo®️ assay as part of their high-throughput drug screening in a panel of 60 human adherent and non-adherent cancer cell lines: https://bit.ly/4dhUxyq

Pharma multinational, Sanofi, and pioneers in targeted alpha therapies in oncology, Orano Med, have entered a partnership to develop next-generation radioligand therapies (RLTs) using lead-212 alpha-emitting isotopes, which follows a recent announcement between Orano Med, RadioMedia and Sanofi to advance RLTs in rare cancers, focusing on one late-stage project, AlphaMedix™. Targeted alpha therapy relies on combining the ability of biological vectors to target cancer cells with the short-range and highly energetic cell-killing capabilities of alpha-emitting radioisotopes. The vector directs the radioisotope to the target cancer cells expressing the specific marker. This unique mechanism of action aims to damage or destroy target cancer cells, while limiting impact on nearby healthy cells. Read more here👇

🚀 Exciting Partnership Announcement! 🚀 Ariceum Therapeutics and ITM Isotope Technologies Munich SE have joined forces to enhance the supply of Actinium-225 (Ac-225), a vital component in the fight against cancer! 🔬 This collaboration aims to meet the growing global demand for Ac-225, crucial for developing innovative targeted radiopharmaceuticals, including satoreotide—specifically designed for aggressive cancers like small cell lung cancer and Merkel Cell Carcinoma. 💡 With Ac-225's unique ability to emit high-energy alpha particles, this partnership paves the way for precision therapies that can effectively target tumor cells while protecting healthy tissue. As Ariceum's CEO Manfred Rüdiger states, “This agreement ensures a reliable supply of Ac-225, enabling us to advance innovative therapies for hard-to-treat cancers.” ITM’s CEO Dr. Andrew Cavey adds that this partnership is key in meeting global demands. Together, they are set to revolutionize cancer treatment and expand access to cutting-edge solutions! 🌍✨ 👉 Click on the link below for more details! #CancerResearch #GlobalMarketAccess #HealthcareAdvancements #Innovation #Partnership #Radiopharmaceuticals #MarketAccess #MarketAccessToday

📢 PRESS RELEASE: Anocca Submits Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer We are pleased to announce the CTA submission, following successful validation, for our multi-asset trial VIDAR-1. The first product in this trial, ANOC-001, will target mutant KRAS G12V, in patients with advanced pancreatic cancer. Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect ~90% of pancreatic cancer patients. There is a less than 10% five-year survival rate for patients with PDAC, with no definitive treatments for advanced patients at present. Subject to approval of the CTA, the study will initiate in Q2, 2025. 🔗Please see the press release here: https://lnkd.in/ggurQFKy #Biotech #Pharma #ClinicalTrial #CancerResearch #Oncology #TCR #CellAndGeneTherapy

MacroGenics’ stock dropped by as much as 70% Friday morning after the biotech disclosed five deaths in the Phase II TAMARACK trial for its investigational antibody-drug conjugate vobramitamab duocarmazine in metastatic castration-resistant prostate cancer. Two of the five fatalities were found to be unrelated to MacroGenics’ investigational ADC vobra duo, while the other three are still under investigation. MacroGenics has had a history of patient deaths in its trials. In September 2021, the biotech posted Phase I data for vobra duo, revealing two fatal grade 5 toxicities—one with an unknown cause and the other attributable to COVID-19. Nearly a year later, in June 2022, MacroGenics reported seven patient deaths, this time in connection with its investigational antibody enoblituzumab, which also targets the B7-H3 antigen, forcing the company to discontinue its Phase II study in head and neck cancer. #biotech #biopharma #deaths #ADC #mCRPC #prostatecancer